You are using an outdated browser. Please upgrade your browser to improve your experience and security.

VYXEOS mechanism of action

VYXEOS is the first dual-drug liposomal encapsulation that has been shown to deliver daunorubicin and cytarabine at a fixed molar ratio over a prolonged period of time1-4

  • The 1:5 molar ratio of daunorubicin and cytarabine was shown to be synergistic in killing leukemia cells in vitro and in murine models1
  • This ratio was shown to be maintained in the plasma for up to 24 hours in a Phase 1 clinical trial4

See the overall survival data for VYXEOS compared to 7+3a in adults with newly-diagnosed t-AML or AML-MRC1

Key highlights

Based on animal studies…

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.